Rajthanee Hospital PCL

Rajthanee Hospital PCL has a market price of 13.2 THB, with a market cap of 3.87 billion THB, and a price-to-earnings ratio of 13.13, which is in line with the industry median. The company's price-to-book ratio of 1.79 suggests a moderate premium over its book value, while its enterprise value to EBITDA of 13.79 indicates a valuation that is consistent with industry norms. The company's profitability is reflected in a return on equity of 13.62% and a return on assets of 6.87%, both of which are above the industry median. The operating margin of 14.0% and net profit margin of 10.77% indicate strong profitability relative to its peers. The company's gross profit margin of 24.4% is also in line with the industry average. Geographically, Rajthanee Hospital PCL is concentrated in Thailand, with all operations based in Phra Nakhon Si Ayutthaya Province. The company operates two hospitals and multiple medical centers, with no disclosed international operations. This concentration may expose the company to local economic and regulatory risks. The company's revenue growth has been modest, with a year-over-year increase of 2.1% in the most recent fiscal year. Looking ahead, the company is projected to maintain a similar growth rate, with a 2.3% increase expected in the next fiscal year. The company's capital expenditure of -158.57 million THB indicates a reduction in investment, which may affect long-term growth. The company's liquidity position is characterized by a current ratio of 0.71, which is below the industry median, indicating potential short-term liquidity constraints. The debt-to-equity ratio of 0.65 suggests a moderate level of leverage, with long-term debt of 1.41 billion THB. The company's free cash flow of 182.04 million THB provides some flexibility, but the negative net cash position after subtracting total debt raises concerns about liquidity. Recent filings and transcripts indicate that the company has not issued any new shares in the past year, and there are no immediate plans for a public offering. The company's risk assessment indicates a low probability of dilution, with no near-term pressure from share issuance. The company's risk profile is characterized by medium liquidity risk and low dilution risk.